Astellas Pharma Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALPMY Over the counter 2834 www.astellas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Astellas Pharma Inc.

U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy - Jan 8th, 2025 11:30 pm
China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer - Jan 8th, 2025 9:55 am
Astellas and Sangamo sign capsid deal for neurological diseases - Dec 20th, 2024 9:37 am
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - Dec 19th, 2024 7:30 am
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - Dec 19th, 2024 7:30 am
Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves - Dec 5th, 2024 1:49 pm
How Astellas juggles the moving parts of cancer precision medicine development - Dec 5th, 2024 7:21 am
Astellas and DOHC partner to pilot digital solution for heart failure management - Nov 21st, 2024 4:01 pm
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management - Nov 20th, 2024 6:00 pm
FDA issues CRL to Astellas’ IZERVAY sNDA for geographic atrophy - Nov 20th, 2024 9:26 am
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer - Nov 19th, 2024 11:35 am
From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies - Nov 13th, 2024 7:42 am
Should Value Investors Buy Astellas Pharma (ALPMY) Stock? - Nov 12th, 2024 2:40 pm
Astellas withdraws Europe ACP application for AMD treatment - Oct 28th, 2024 9:50 am
FDA approves Astellas’ VYLOY for gastric cancer treatment - Oct 21st, 2024 9:15 am
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer - Oct 18th, 2024 6:13 pm
Astella’s iota receives FDA go-ahead for bladder implant trial - Oct 14th, 2024 3:48 pm
FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device - Oct 10th, 2024 5:00 pm
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause - Oct 10th, 2024 7:00 am
Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application - Oct 9th, 2024 11:00 am